[Long-term treatment and prevention of uric acid urolithiasis with allopurinol].
29 patients (20 male and 9 female, average age 55 years), suffering from uric acid-urolithiasis were treated with Zyloric-U over a period of 8 to 20 months. Two of them had side effects (cutaneous symptoms). In all other cases the stones were dissolved or diminuated. Chemical analysis demonstrated a significant reduction of serum uric acid as well as a decrease of calcium secretion in the urine. Yet the urine-pH of 5 remained unchanged. In some cases, if the patients excreted gravel and if the level of uric acid was not lowered sufficiently the dose was raised to twice 300 mg. A report of the follow-up of these patients shall be published later.
D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D014527:Uric Acid / Q000378:metabolism; D014545:Urinary Calculi / Q000188:drug therapy* / Q000517:prevention & control
D014527:Uric Acid; D000493:Allopurinol
Langzeitbehandlung und Prophylaxe der Harnsäuresteine mit Allopurinol.